Case Report: CD20/BCMA bispecific CAR-T therapy for progressive multiple sclerosis
Two patients with secondary progressive multiple sclerosis (SPMS) were treated with C-CAR168, a CAR-T therapy targeting CD20 and BCMA. One patient improved in various neurological functions over 12 months, while the other experienced halted progression over 6 months. The therapy also showed infiltration in the cerebrospinal fluid, depleting certain immune cells and normalizing inflammation markers.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not yet assessed
- Mechanism
- Not yet assessed
- Evidence strength
- Not yet assessed
- Outcome
- Not yet assessed
Why it matters
These findings suggest potential benefits of CAR-T therapy for SPMS, demonstrating a mechanism of action involving immune modulation and improvement in patient symptoms. However, the small sample size limits the strength of these conclusions.
What this does not prove
This is a case report with a very small sample size, not allowing for generalizable conclusions about efficacy.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Case report
- Participants / samples
- 2 · Two SPMS patients reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- SPMS
- Publication date
- 2026-09-29
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceCase Report: CD20/BCMA bispecific CAR-T therapy for progressive multiple sclerosis. ↗DOI: 10.3389/fimmu.2026.1965459
Supporting passages (10)
study designCase Report
sample size2
sample size basisTwo SPMS patients are reported with C-CAR168 treatment, a bispecific CD20/BCMA CAR-T product, achieving 12- and 6-month drug-free remission.
relevant ms typesSPMS
publication date2026-09-29
interventionTwo SPMS patients are reported with C-CAR168 treatment, a bispecific CD20/BCMA CAR-T product, achieving 12- and 6-month drug-free remission.
follow up12- and 6-month drug-free remission
findingsPatient 001 (EDSS 4.0→3.0) showed improvement of oculomotor dysfunction, ataxia, and cognitive impairment.
findingsPatient 002 (EDSS 6.5→6.0) demonstrated halted lower-limb progression and relieved bowel/bladder dysfunction.
limitationsTitle: Case Report: CD20/BCMA bispecific CAR-T therapy for progressive multiple sclerosis.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.